Novartis Vaccines & Diagnostics, Gmbh

Chiron Corporation

Novartis Ag

Vivien W Chan

Christoph Reinhard

Anne B Jefferson

Giulia C Kennedy

Joerg Kaufmann

Lewis T Williams

Jaime A Escobedo

Filippo M Randazzo

Pablo Dominguez Garcia

George Lamson

Julie Sudduth-Klinger

Rhonda Hansen

Michael Rohan

Edward J Moler

Marion Wiesmann

Carla C Heise

Venkatakrishna Shyamala

Greg Harrowe

Hong Xin

Hamiduddin Khoja

Timothy D Dawes

Glenn C Michelson

A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, wherein the patient is a cancer patient with drug-resistant cancer, wherein the compound of Formula I is as defined in the application.

Methods for treating drug resistant cancer

The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.

Gene products differentially expressed in cancerous cells

HX2004-6 polypeptide expressed in cancerous cells

The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.

Detection of colon or breast cancer by measuring TTK polynucleotide expression

Detection of colon or breast cancer by measuring TTK polypeptide expression

Determining prognosis of colon or breast cancer by measuring TTK expression

The invention provides polynucleotides encoding Notch receptor ligands, encoded polypeptides, and antibodies specific to the polypeptides. Also provided are methods and compositions for enhancing or inhibiting angiogenesis as well as modulating immune responses.

Notch receptor ligands and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Vivien W Chan